Dr Evan Ingley
PhD, BSc(Hons1)

I am a Lecturer in Clinical Biochemistry and have been a member of staff since March 2017. I graduated with a first-class Honours degree in Zoology from Canterbury University (New Zealand) in 1988. I then moved to Canberra (ACT) and undertook a PhD at the John Curtin School of Medical Research (Australian National University, ANU) on a full ANU Postgraduate Scholarship, graduating in 1992. I undertook my post-doctoral training at the Frederich Meischer Institute for Biomedical Research in Basel (Switzerland) from 1991-1994 before returning to Australia and working with Professor Peter Klinken at the University of Western Australia and subsequently at the Harry Perkins Institute of Medical Research (formerly know as the Western Australian Institute for Medical Research, WAIMR). In 2006 I started my own research group at the Perkins Institute (the Cell Signalling Group) focusing on the molecular pathways controlling cancer and blood development. My research group remains located at the Perkins Institute (QEII campus, Nedlands) and I am also the Chair of the Perkins Institute Animal Ethics Committee. At Murdoch University I am the unit coordinator for BMS323 (Clinical Biochemistry I) and BMS423 (Clinical Biochemistry II) and also deliver components of BIO247 (Biochemistry).

• BMS323 – Clinical Biochemistry I (Unit Coordinator).
• BMS423 – Clinical Biochemistry II (Unit Coordinator).
• The University of Western Australia (School of Biomedical Sciences, 3 lectures on the Cell Cycle, Cancer and Apoptosis, and 2 lectures on Cancer Cell Signalling).

• Cell signalling mechanisms involving Src family tyrosine kinases that control mature red blood cell membrane-cytoskeleton dynamics.
• Molecular pathways involving Src family kinases down-stream of the Erythropoietin (Epo) receptor in RBC progenitors leading to proliferation, viability and differentiation.
• Understanding the pathways and potential therapeutic application of the scaffolding protein AFAP1L1 (Actin Filament Associating Protein 1-Like-1) in sarcoma/cancer cell migration, invasion and metastasis.
• Using personalized genomics to better diagnose and treat sarcoma patients.

• Signalling networks in the regulation of red blood cell integrity and survival.
• Control of bone cancer cell migration and invasion by the scaffold protein AFAP1L1.
• Studying the magnitude of the effect of enzyme variations on the ability of young cancer patients to handle High-Dose-Methotrexate (HDMTX) treatment, as HDMTX can causes severe toxicities.
• Identifying new therapy options for sarcoma patients through personalized genomic medicine.

• Project Grant (2016-2019). $600,000. P. Blancafort, E. Ingley, A. Redfern, A Sorolla-Bardaji, N. Taylor, A. Woo. “Discovery and Characterisation of a Cancer Driver in a New Subtype of Aggressive Breast Cancer.” Cancer Council Australia.
• Project Grant (2017-2019). $247,758. R. Clifford, Z. Ibrahim, E. Ingley, R. McKinnon, N. Gottardo, J. Marsh, J. Beilby, B. Delfante, L. Cheung. “Methotrexate in Seriously Sick Kids (MiSSK); personalised Cancer Treatment using pharmacogenomics to improve patient outcomes and reduce the cost of cancer care when treating seriously sick children.” Telethon – Perth Children’s Hospital Research Fund 2016 – Round 5.
• Research Grant (2019). $20,000. E. Ingley, D. Wood, D. Adams, V. Iyer. “Dedifferentiation of MDM2 amplified low grade liposarcoma: Comparative genomics and transcriptomics to determine the mechanisms of tumour progression and precision targets.” Australia and New Zealand Sarcoma Association (ANZSA).
• Project Grant (2017-2018) $100,000. E. Ingley (CIA). “Control of osteosarcoma cell migration and invasion by the scaffold protein AFAP1L1.” Cancer Council of Western Australia.
• Sarcoma Sock-it-to-Sarcoma! Project Grant (2016-2018), $5,000. E. Ingley. Hollywood Private Hospital Research Foundation.
• Project Grant (2016) $100,000, P. Blancafort, A Redfern, C. Curtis, E. Ingley, A. Woo, N. Taylor, A. Sorolla Bardaji, “Discovery and Characterization of a Cancer Driver in a New Subtype of Aggressive Breast Cancer”, Cancer Council of Western Australia.
• Sock-it-to-Sarcoma Project grant (2015-2018), $72,000. D. Wood and E. Ingley. Hollywood Private Hospital Research Foundation.
• Project Grant, (2015) $100,000. E. Ingley (CIA). “Defining signalling pathways underlying red blood cell development, function and Disease”. Cancer Council of Western Australia.
• Sock-it-to-Sarcoma Ad Hoc Fellowship (2014-2016), 50% $80,000pa E. Ingley (CIA). Hollywood Private Hospital Research Foundation.
• SunSuper Ride to Conquer Cancer Ad Hoc Fellowship (2014-2016), $80,000 E. Ingley (CIA). Harry Perkins Institute of Medical Research.
• Project Grant (2014) $100,000. E. Ingley (CIA). “Role of Lyn tyrosine kinase in blood development and disease”. Cancer Council of Western Australia.
• NHMRC Project Grant APP1010726 (2011, 2012, 2013) $347,931. L. Hool, E. Ingley (CIB), B. Corry, “Identifying the site/s of modification on the human L-type Ca2+ channel protein isoforms during oxidative stress with reference to development of a therapeutic target”. National Health and Medical Research Council.
• Project Grant, (2013) $100,000. E. Ingley (CIA). “Control of nuclear/cytoplasmic shuttling by Liar/AnkRD54”. Cancer Council of Western Australia.
• Project Grant (2013) $16,500. E. Ingley (CIA). “Defining the molecular mechanism of AFAP1L1 regulation of invasion/metastasis in sarcoma through the novel Lyn-AFAP1L1-Vav2/Nck2-actin pathway”. Royal Perth Hospital Medical Research Foundation.
• NHMRC Project Grant #634352 (2010, 2011, 2012) $508,986. E. Ingley (CIA) Inhibitors of Src family kinase signalling’. National Health and Medical Research Council.
• Project Grant (2012) $15,000. E.Ingley (CIA). “Dissecting the control of Src Family Kinases through Structural Insights of their Interaction with Cbp/PAG1”. Royal Perth Hospital Medical Research Foundation.
• Project Grant (2012) $90,000. E. Ingley (CIA). “Control of nuclear/cytoplasmic shuttling by Liar”. Cancer Council of Western Australia.
• Project Grant (2011) $15,000. N. Kucera, N. Slavova-Azmanova, E. Ingley (CIC). “Structure/Function analysis of the Liar/AnkRD54 Pathway.” Royal Perth Hospital Medical Research Foundation.
• Project Grant, (2010) $70,000. E. Ingley (CIA). “The Src Homology 2 (SH2) interactome”. Cancer Council of Western Australia.
• Senior Research Fellowship, (2010-2013) $400,000. E. Ingley (CIA). Cancer Council of Western Australia.
• NHMRC Project Grant #513714 (2008, 2009, 2010) $751,000. E. Ingley (CIA), M. Hibbs, K-P. Lam, S. P. Klinken. ‘Lyn Tyrosine Kinase Signalling Cascades’. National Health and Medical Research Council.
• NHMRC Project Grant #513724 (2008, 2009, 2010) $228,250. I. M. Dick, R. L. Prince, S. G. Wilson, E. Ingley (CID), ‘Functional Effects of Polymorphic Variation of the Aromatase (CYP19) Gene on Enzyme Activity: Relationship to Disease’. National Health and Medical Research Council.
• Project Grant (2009) $13,000. E. Ingley (CIA). “Towards a proteome-wide analysis of phosphor-tyrosine-SH2 domain interactions and its potential use in clinical diagnosis.” Royal Perth Hospital Medical Research Foundation.
• NHMRC Project Grant #403987 (2006, 2007, 2008) $197,250. E. Ingley (CIA). “Developing Novel Molecules to Down-Regulate Src Family Tyrosine Kinases.” National Health and Medical Research Council.
• Project Grant (2008) $13,500. E. Ingley (CIA). “Regulating the cytoskeleton of cancer/leukaemia cells: Role of a new signalling pathway.” Royal Perth Hospital Medical Research Foundation.
• Project Grant (2007, 2008) $13,000. E. Ingley (CIA). “LACM: A novel multi-domain protein with potential as an oncogene involved in cancer.” Royal Perth Hospital Medical Research Foundation.
• NHMRC Equipment Grant (2008) $75,490. P. G. Arthur, L. C. Hool, M. D. Grounds, P. A. Fournier, T. Shavlakadze, A. Filipovska, S. A. Dunlop, M. Fitzgerald, C. S. Bond, B. A. Corry, E. Ingley (CIK) ‘NHMRC Equipment Grant – Capillary Liquid Chromatography System for Proteomic Applications’. National Health and Medical Research Council.
• NHMRC Equipment Grant (2008) $74,645. E. Ingley (CIA), A. Barker, P. J. Leedman. ‘NHMRC Equipment Grant – Biorad Biologic Duoflow FPLC and Profinia Instrument’. National Health and Medical Research Council.
• NHMRC Equipment Grant (2007) $95,000. Dr P. J. Rigby, Dr K. A. Heel, Prof P. J. Leedman, Prof G. Morahan, Dr W. Y. Langdon, Dr R. Ganss, Dr E. Ingley, Prof D. Ravine 2007, ‘NHMRC Equipment Grants – Becton Dickinson FACS Canto II Flow Cytometer with High Throughput Sampler’.
• NHMRC Equipment Grant (2007) $44,000. Dr E. Ingley (CIA), Dr L. N. Winteringham. ‘NHMRC Equipment Grants – RoboSep Magnetic cell sorter’.
• NHMRC Equipment Grant (2007) $34,499. Dr L. C. Hool, Dr P. G. Arthur, Dr B. A. Corry, Dr E. Ingley, Dr J. M. Alvarez, Dr W. Macdonald. ‘NHMRC Equipment Grant 2007 – MultiClamp 700B Amplifier ad Nikon Ti-U Inverted Microscope for performing Studies on Membrane Conductance in Conjunction with patch-Clamp Ion Channel Recordings’.
• Royal Perth Hospital Medical Research Foundation Project Grant (2006, 2007) $12,000. Dr. E. Ingley (CIA). “Developing novel molecules to down-regulate the tyrosine kinase Lyn.”
• NHMRC Project Grant #303101 (2004, 2005, 2006) $489,750. Dr. E. Ingley (CIA) and Prof. S.P. Klinken (CIB). “Erythroid molecular cascades involving the tyrosine kinase Lyn.”
• WAIMR WMR21 (2003, 2004, 2005) $325,000. Prof S.P. Klinken, Assoc. Prof. R.F. Minchin, Dr. E. Ingley, Prof. P.J. Leedman “The biochemical and pharmacological regulation of erythropoiesis.”
• NHMRC Project Grant #139008 (2001, 2002, 2003) $435,475. Dr. E. Ingley (CIA) and Prof. S. P. Klinken (CIB). “Characterization of novel regulators of erythropoiesis.”
• Royal Perth Hospital Medical Research Foundation Project Grant (2001, 2002) $11,000. Dr. E. Ingley. “Generation of transgenic mice expressing an inhibitor of cytokine and nuclear hormone cross-talk specifically in the erythroid compartment.”

Invited Conference Presentations:

• Ingley, E. (2018) “AFAP1L1 and Metastatic Invasion in Sarcoma.” WA Sarcoma Awareness Week Symposium 2018, Perth, WA, Australia.
• Ingley, E. (2017) “Molecular Pathways of Sarcoma Cell Invasion.” WA Sarcoma Awareness Week Symposium 2017, Perth, WA, Australia.
• Ingley, E. (2017) “Signalling networks in the regulation of red blood cell integrity and survival.” 22^nd Annual Lorne Proteomics Symposium, Lorne, VIC.
• Ingley, E. (2016) “Controlling bone cancer cell migration and invasion: The AFAP1L1 pathway.” Combined Biological Sciences Meeting (CBSM), Perth, WA.
• Ingley, E. (2016) “Src family tyrosine kinase pathways in sarcoma: Discovery interactomics, drug resistance and invasion.” WA Sarcoma Awareness Week Symposium 2016, Perth, WA, Australia.
• Ingley, E. (2016) “Csk-binding protein controls red blood cell development via regulation of Lyn tyrosine kinase activity.” 8^th Garvan Signalling Symposium, Sydney, NSW.
• Ingley, E. (2015) “Regulation of Lyn kinase activity by Csk binding protein (Cbp/PAG1): Importance for erythropoiesis, Epo-R signalling and red blood cells.” 7^th Barossa Signalling Meeting, Barossa Valley, SA.
• Ingley, E. (2015) “Protein-protein interactions and protein modification identification and analysis – focus on tyrosine kinase pathways in cancer.” ASBMB Fremantle meeting, WA.
• Ingley, E. (2015) “Src family tyrosine kinase pathways in sarcoma: Discovery interactomics, drug resistance and invasion.” WA Sarcoma Awareness Week Symposium 2015, Perth, WA, Australia.
• Ingley, E. (2014) “Regulation of sarcoma cell invasion and invadopodia formation by AFAP1L1 through a Lyn/SFK-AFAP1L1-Nck2/Vav2 pathway.” Cancer Council Research Symposium, Perth, WA, Australia.
• Ingley, E. (2014) “Controlling sarcoma cell migration and invasion through a novel SFK-AFAP1L1-Nck2/Vav2 pathway.” Garvan Signalling Symposium, Sydney NSW, Australia.
• Ingley, E. (2014) “Regulation of sarcoma cell invasion and invadopodia formation by AFAP1L1 through a Lyn/SFK-AFAP1L1-Nck/Vav2 pathway.” WA Sarcoma Awareness Week Symposium, Perth, WA, Australia.
• Ingley, E. (2013) “Lyn signalling pathways in neoplastic cells.” The 4^th ACBRC and 2013 International Symposium on Ageing Biology and Diseases, Hangzhou, China.
• Ingley, E. (2013) “Gain-of-function Lyn induces anemia – appropriate Lyn activity is essential for normal erythropoiesis and Epo-receptor signaling.” Barossa Signalling Meeting, Barossa, SA.
• Ingley, E. (2012) “AFAP1L1 is strongly associated with malignant osteosarcoma, liposarcoma, and leiomyosarcoma, localizes to invadopodia and controls cell invasion by a novel Lyn/AFAP1L1/Vav2-Nck2 pathway.” ComBio2012, Adelaide, SA, Australia.
• Ingley, E. (2012) “AFAP1L1 is strongly associated with malignant osteosarcoma, liposarcoma, and leiomyosarcoma, localizes to invadopodia and controls cell invasion by a novel Lyn/AFAP1L1/Vav2-Nck2 pathway.” WA Cancer Council Research Symposium, Perth, WA, Australia.
• Ingley, E. (2011) “Controlling erythropoiesis and Epo-receptor signalling through the tyrosine kinase Lyn and its substrate/scaffold Cbp/PAG1.” ComBio2011, Cairns, QLD, Australia.
• Ingley, E. (2010) “Controlling Cell Shape: The Lyn-LACM-Vav2/Nck2 Pathway.” 5^th Garvan Signalling Symposium, Sydney, NSW, Australia.
• Ingley, E. (2010) “Towards an SH2 interactome: Using a pY-specific Y2H system to identify and analyse novel signalling pathways in erythropoies and cancer.” OzBio2010, Melbourne, VIC, Australia.
• Ingley, E. (2009) “Understanding Src Family Tyrosine Kinase Signalling and Tissue Repair.” LIWA 2009 Lung and Biological Sciences Symposium, Perth, WA, Australia.
• Ingley, E. (2008) “New Src Family Tyrosine Kinase Pathways – A Lyn Perspective.” New Directions in Leukaemia Research, Sunshine Coast, QLD, Australia.
• Ingley, E. (2007) “The SH2 interactome: Development and utility of a pY-specific Y2H system to identify and analyze signaling pathways.” American Society for Biochemistry and Molecular Biology, Experimental Biology Meeting, Washington, DC, USA.
• Ingley, E. (2007) “Src Family Kinases: Regulating their Activity, Levels and Identifying New Pathways.” Inhibitors of Protein Kinases, Warsaw, Poland.
• Ingley, E. (2007) “Protein Interaction Identification/Analysis Using Y2H, pY-Y2H, pS/T-Y2H, Ac-Y2H and Y3H.” 17^th Annual (Mundaring Weir) Symposium, Satellite Meeting of the Australian Society for Biochemistry and Molecular Biology (ASBMB), 2001, Fremantle Weir, WA, Australia.
• Ingley, E. (2006) “Dual Inactivation of Src Kinase Lyn by Cbp, via Phosphorylation and Ubiquitination.” 4^th Annual Protein Kinase Targets – Drug Discovery and Design, Boston, MA, USA.
• Ingley, E. (2006) “Involvement of the Lyn Interactome in the Regulation of Erythropoiesis.” American Society of Hematology, 48th Annual Meeting and Exposition, Orlando, Florida, USA.
• Ingley, E. (2005) “Controlling Lyn signalling; phosphorylation and ubiquitination pathways involving Cbp, SOCS1 and Csk/Ctk.” 2^nd Barossa Signalling Meeting, Barossa Vally, SA, Australia.
• Ingley, E. (2005) “Cellular Signalling.” 2005 Royal College of Pathologists of Australia (RCPA) BPS course. Perth, WA, Australia.
• Ingley, E., Schneider, J. R., McCarthy, D. J., Tilbrook, P. A., Tsai, S., and Klinken, S. P. (2004) “Controlling Lyn Signalling; phosphorylation and ubiquitination pathways involving Cbp, SOCS1 and Csk/Ctk.” ComBio 2004, Perth, WA, Australia.
• Ingley, E. (2003) “Controlling Lyn signalling; phosphorylation and ubiquitination pathways involving Cbp/PAG, SOCS1, Csk/Ctk and AFAPb.” 15^th Lorne Cancer Conference, Lorne, VIC, Australia.
• Ingley, E. (2001) “Trip-1 modulates cytokine and nuclear hormone signalling in erythroid cells.” 13^th Lorne Cancer Conference, Lorne, VIC, Australia.
• Ingley, E. (1992) “Studies on a New Serine/threonine Kinase RAC.” Novel Protein Kinase Workshop, 8^th International Conference on Second Messengers and Phosphoproteins , Glasgow, Scotland.

Invited Institutional Presentations:

• Ingley, E. (2018) “Signalling networks in the regulation of red blood cell integrity and survival.” Curtin Health Innovation Research Institute, Curtin University, WA.
• Ingley, E. (2015) “The first oncogene (and its family); still much to discover for blood and cancer.” Harry Perkins Institute of Medical Research, University of Western Australia.
• Ingley, E. (2015) “Signalling pathways intersected by the Src family kinase Lyn involved in blood development and cancer.” School of Chemistry and Biochemistry, University of Western Australia.
• Ingley, E. (2014) “Signalling pathways intersected by the Src family kinase Lyn involved in blood development and cancer.”  Department of Medicine, University of Verona, Verona, Italy.
• Ingley, E. (2014) “The role of the tyrosine kinase Lyn in erythropoiesis and red blood cell leukaemia.” Department of Neurology, Dresden University of Technology, Dresden, Germany.
• Ingley, E. (2012) “AFAP1L1 is strongly associated with malignant sarcomas, localizes to invadopodia and controls cell invasion by a novel Lyn/AFAP1L1/Vav2-Nck2 pathway.” Endocrinology Department, SCGH, Nedlands, WA, Australia.
• Ingley, E. (2010) “Src Family Tyrosine Kinase Networks in Hematology / Oncology – A Lyn Perspective.” Department of Biochemistry, University of Melbourne (Bio21), Melbourne, VIC, Australia.
• Ingley, E. (2009) “Src family tyrosine kinase signalling in hematology/oncology.” Department of Endocrinology, SCGH, Nedlands, WA, Australia.
• Ingley, E. (2008) “Src Family Tyrosine Kinase Pathways involved in Erythropoiesis and Cancer– A Lyn Perspective.” Garvan Institute of Medical Research, Sydney, NSW, Australia.
• Ingley, E. (2008) “New Src Family Tyrosine Kinase Pathways – A Lyn Perspective.” Biochemistry Department, Monash University, Melbourne, VIC, Australia.
• Ingley, E. (2007) “Analysing signalling pathways initiated by the tyrosine kinase Lyn.” Institute for Molecular and Cell Biology, Immunos, Biopolis, Singapore.
• Ingley, E. (2007) “The Lyn Interactome: Regulation of Erythropoiesis.” Fremantle Hospital, Fremantle, WA, Australia.
• Ingley, E. (2007) “Analysing signalling pathways initiated by the tyrosine kinase Lyn.” Tumour Biology Branch, Ludwig Institute of Cancer Research, Melbourne, VIC, Australia.
• Ingley, E. (2006) “The Lyn Interactome: Regulation of Erythropoiesis.” New York Blood Center, New York, USA.
• Ingley, E. (2006) “Erythroid Signalling Pathways: Src Family Kinase Regulation.” Immunology Division, WEHI, Melbourne, VIC, Australia.
• Ingley, E. (2005) “Unravelling Signalling Pathways: Molecular Interactions of the Tyrosine Kinase Lyn.” Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth, WA, Australia.
• Ingley, E. (2004) “Molecular Cascades Operating Through the Tyrosine Kinase Lyn.” Centre for Immunology and Cancer Research, Brisbane, QLD, Australia.
• Ingley, E. (1994) “The Pleckstrin Homology (PH) Domain of the serine/threonine protein kinase RAC: A new signalling motif. Karolinska Institute, Stockholm, Sweden.
• Ingley, E. (1991) “Characterization of a Receptor for Interleukin 5 on Human Eosinophils and the Myeloid Leukaemia Line HL-60.” Frederick Miescher Institute, Basel, Switzerland.
• Ingley, E. (1991) “Characterization of a Receptor for Interleukin 5 on Human Eosinophils and the Myeloid Leukaemia Line HL-60.” Department of Zoology, University of Canterbury, Christchurch, New Zealand.

Conference Scientific/Organizing Committees

• Lorne Cancer Conference, 2008-2019.
• New Directions in Leukemia Research, 2008.
• ComBio2013, Perth, WA, Australia, 2013.

Peer Review

Fellowships, Project Grant and Program Grant Assessments

• Scientific assessor for NHMRC Project Grant applications, since 1997.
• Scientific assessor for Cancer Council Project Grant applications (NSW, QLD, SA) 1998-2010.
• Scientific assessor for National Heart Foundation Project Grant applications, 2003-2010.
• Scientific assessor for the Italian Association for Cancer Research, since 2004.
• Grant/Fellowship Review Panel member for the Cancer Council WA, since 2006.
• Scientific assessor for the Swiss National Science Foundation, since 2007.
• Grant Review Panel (GRP) member for NHMRC, 2007-2009, 2014-2015.
• Scientific assessor, Health Research Council (New Zealand) Program Grants, since 2012.
• Scientific assessor for the Czech Science Foundation (GACR) grants, since 2009.
• Scientific assessor for Italian Telethon Project Grants, since 2012, 2013.
• Scientific assessor Cancer Institute NSW Translational Program Grants, Fellowships, and Translational Project Grants, since 2013.
• Scientific assessor for NHMRC Program Grants, since 2013.
• Scientific assessor for NHMRC Priority Driven Cancer Research Scheme, 2011.
• Scientific assessor for the Irish Health Research Board Fellowships, since 2001.
• Scientific assessor for NHMRC Senior Fellowships, since 2010.

Journal Refereeing

• The International Journal of Biochemistry and Cell Biology.
• Molecular and Cellular Endocrinology.
• Genomics.
• Journal of Cell Science.
• Blood.
• Molecular Endocrinology.
• FEBS Letters.
• Clinical and Experimental Pharmacology and Physiology.
•  Cell Communication and Signaling.
• PlosOne.
• Oncogene.
• Proceedings of the National Academy of Sciences, USA.
• Biochemica Biophysica Acta.
• Journal of Cellular and Molecular Medicine.
• IUBMB Life.
• Molecular and Cellular Biology.
• World Journal of Methods.
• Cell Death and Differentiation.
• World Journal of Cardiology.
• BMC Cancer.
• BMC Research Notes.
• British Journal of Haematology.

Editorial Board Member

• World Journal of Biological Chemistry (since 2013).
• Frontiers in Cell and Developmental Biology – Stem Cells (since 2013).
• Journal of Zoo Biology (since 2013).

Patent Assessment

• Expert witness for Wry and Associates (Patent and Trademark Attorneys), 2002.

Institutional Committees:

• Perkins Institute Animal Ethics Committee Chair (2016-present)
• Perkins Institute Animal Ethics Committee Deputy Chair (2014-2016)
• Royal Perth Hospital Institutional Biosafety Committee (1998-2008)
• Perkins Institute Institutional Biosafety Committee (2013-2016)
• Cancer Council of Western Australia Grants/fellowships Review Panel (2006-present)

Membership of Professional Societies:

• Australian Society for Biochemistry and Molecular Biology (since 1989).
• The Australian Society for Medical Research (since 1997).
• The American Society of Hematology (since 2005).
• The American Society of Biochemistry and Molecular Biology (since 2006).
• The Australian and New Zealand Society for Cell and Developmental Biology (since 2007).
• The American Society of Cell Biology (since 2008).
• International Society of Experimental Hematology (2010-2013).
• Australia and New Zealand Sarcoma Association (since 2019).

Current Students:

• Jun Lu, School of Health and Medical Sciences, UWA, co-supervised with Prof. D. Wood, Prof. M. Zheng, Dr. C. Grove.
• Zayad Ibrahim, School of Surgery and School of Medicine and Pharmacology, UWA, co-supervised with Prof. R. Clifford, Dr, R. McKinnon, Dr. H. McLeod.

Previous Students:

• Rachel Jones, School of Population Health (UWA), co-supervised with Prof. E. Moses, Prof. D. Wood and A/Prof. D. Uligati, degree conferred 2018.
• P. Muralidharan, School Anatomy, Physiology and Human Biology (UWA), co-supervision with A/Prof. L. Hool, degree conferred 2015.
• S.R. Tie, School of Biomed., Biomol. and Chem. Sci., UWA, co-supervision with Prof. P. Arthur.
• W. Wallefeld, Fac. Med. Dent. Health Sci., UWA, co-supervision with Prof. N. Laing and Dr. K. Nowak, degree conferred 2011.
• D. McCarthy, Fac. Med. Dent. Health Sci., UWA, co-supervision with Prof. S.P. Klinken, degree conferred 2009.
• A. Samuels, Fac. Med. Dent. Health Sci., UWA, co-supervision with Prof. S.P. Klinken, degree conferred 2007.
• D. Chappell, Dept. Biochem., UWA, co-supervision with Prof. S.P. Klinken. Degree conferred 2000.
• M. Andjelkovic, P. Turowski and T. Millward, Friedrich Miescher Institute / University of Basel, Switzerland, co-supervision with Dr. B.A. Hemmings, all degrees conferred.

Journals

• Lu, J., Wood, D., Ingley, E., Koks, S., Wong, D., (2021), Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma, Molecular Biology Reports, , , .
• Brown, P., Ingley, E., Zhou, Y., (2019), Large expert-curated database for benchmarking document similarity detection in biomedical literature search, Database, 2019, , pages 1 - 66.
• Jones, R., Melton, P., Pinese, M., Rea, A., Ingley, E., Ballinger, M., Wood, D., Thomas, D., Moses, E., (2019), Identification of novel sarcoma risk genes using a two-stage genome wide DNA sequencing strategy in cancer cluster families and population case and control cohorts, BMC Medical Genetics, 20, , pages 69 -.
• Szappanos, H., Muralidharan, P., Ingley, E., Petereit, J., Millar, H., Hool, L., (2017), Identification of a novel cAMP dependent protein kinase A phosphorylation site on the human cardiac calcium channel, Scientific Reports, 7, 1, pages e15118 -.
• Muralidharan, P., Szappanos, H., Ingley, E., Hool, L., (2017), The cardiac L-type calcium channel alpha subunit is a target for direct redox modification during oxidative stress-the role of cysteine residues in the alpha interacting domain, Clinical and Experimental Pharmacology and Physiology, 44, , pages 46 - 54.
• Samuels, A., Louw, A., Zareie, R., Ingley, E., (2017), Control of nuclear-cytoplasmic shuttling of Ankrd54 byPKC, Journal of Biological Chemistry, 8, 3, pages 163 - 174.